Logo image of CBIO

CATALYST BIOSCIENCES INC (CBIO) Stock Fundamental Analysis

NASDAQ:CBIO - Nasdaq - US14888D2080 - Common Stock - Currency: USD

0.5113  -0.01 (-2.65%)

After market: 0.5406 +0.03 (+5.73%)

Fundamental Rating

1

CBIO gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While CBIO seems to be doing ok healthwise, there are quite some concerns on its profitability. CBIO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CBIO has reported negative net income.
CBIO had a negative operating cash flow in the past year.
In the past 5 years CBIO always reported negative net income.
In the past 5 years CBIO always reported negative operating cash flow.
CBIO Yearly Net Income VS EBIT VS OCF VS FCFCBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M

1.2 Ratios

CBIO has a worse Return On Assets (-444.02%) than 97.85% of its industry peers.
Looking at the Return On Equity, with a value of -1257.95%, CBIO is doing worse than 85.97% of the companies in the same industry.
Industry RankSector Rank
ROA -444.02%
ROE -1257.95%
ROIC N/A
ROA(3y)-82.09%
ROA(5y)-65.26%
ROE(3y)-119.61%
ROE(5y)-92.94%
ROIC(3y)N/A
ROIC(5y)N/A
CBIO Yearly ROA, ROE, ROICCBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CBIO Yearly Profit, Operating, Gross MarginsCBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -100K -200K -300K

More info and screens

5

2. Health

2.1 Basic Checks

CBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CBIO has been increased compared to 1 year ago.
There is no outstanding debt for CBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CBIO Yearly Shares OutstandingCBIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
CBIO Yearly Total Debt VS Total AssetsCBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -60.55, we must say that CBIO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CBIO (-60.55) is worse than 97.52% of its industry peers.
There is no outstanding debt for CBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -60.55
ROIC/WACCN/A
WACC10.5%
CBIO Yearly LT Debt VS Equity VS FCFCBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

CBIO has a Current Ratio of 2.88. This indicates that CBIO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CBIO (2.88) is worse than 72.44% of its industry peers.
A Quick Ratio of 2.88 indicates that CBIO has no problem at all paying its short term obligations.
With a Quick ratio value of 2.88, CBIO is not doing good in the industry: 71.12% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.88
Quick Ratio 2.88
CBIO Yearly Current Assets VS Current LiabilitesCBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for CBIO have decreased strongly by -465.60% in the last year.
The Revenue for CBIO has decreased by -100.00% in the past year. This is quite bad
The Revenue has been decreasing by -4.89% on average over the past years.
EPS 1Y (TTM)-465.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-556.25%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y-4.89%
Sales Q2Q%N/A

3.2 Future

CBIO is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -26.45% yearly.
Based on estimates for the next years, CBIO will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y-117.39%
EPS Next 2Y-42.57%
EPS Next 3Y-26.45%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CBIO Yearly Revenue VS EstimatesCBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5M 10M 15M 20M
CBIO Yearly EPS VS EstimatesCBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CBIO Price Earnings VS Forward Price EarningsCBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CBIO Per share dataCBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

CBIO's earnings are expected to decrease with -26.45% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-42.57%
EPS Next 3Y-26.45%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CBIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CATALYST BIOSCIENCES INC

NASDAQ:CBIO (10/30/2023, 8:00:01 PM)

After market: 0.5406 +0.03 (+5.73%)

0.5113

-0.01 (-2.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-26 2023-10-26/amc
Earnings (Next)03-28 2024-03-28/amc
Inst Owners0%
Inst Owner Change-94.58%
Ins Owners1.01%
Ins Owner Change0%
Market Cap19.42M
Analysts43.33
Price Target16.32 (3091.86%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend1.3
Dividend Growth(5Y)N/A
DP-28.85%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17.65%
Min EPS beat(2)-37.25%
Max EPS beat(2)1.96%
EPS beat(4)2
Avg EPS beat(4)26.24%
Min EPS beat(4)-37.25%
Max EPS beat(4)114.01%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-1400%
EPS NQ rev (3m)-1100%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.52
P/tB 5.52
EV/EBITDA N/A
EPS(TTM)-1.37
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0
BVpS0.09
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -444.02%
ROE -1257.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-82.09%
ROA(5y)-65.26%
ROE(3y)-119.61%
ROE(5y)-92.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.88
Quick Ratio 2.88
Altman-Z -60.55
F-Score2
WACC10.5%
ROIC/WACCN/A
Cap/Depr(3y)196.44%
Cap/Depr(5y)217.86%
Cap/Sales(3y)4.29%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-465.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-556.25%
EPS Next Y-117.39%
EPS Next 2Y-42.57%
EPS Next 3Y-26.45%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y-4.89%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y69.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y84.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y84.83%
OCF growth 3YN/A
OCF growth 5YN/A